Israeli Scientists Find Way to Prevent Melanoma Metastasis to the Brain

A group of researchers from the medical school at Tel Aviv University discovered the mechanism by which melanoma cells – the most dangerous type of skin cancer – infiltrate the brain, forming metastases. In an experiment on mice, they managed to block this mechanism, halting the process of cancer spreading to the brain. This discovery could be an important step towards conquering this deadly disease.
Melanoma is the deadliest form of skin cancer. Its insidiousness lies in its ability to grow actively and metastasize to the brain. Such metastases are virtually untreatable, making the prognosis for individuals with advanced melanoma extremely unfavorable. The average survival in such cases rarely exceeds six months.
“Just a few years ago, patients with advanced melanoma died from metastases in other parts of the body – the tumour foci in the brain simply did not have time to form in sufficient volume to cause a fatal outcome,” explains the lead author of the study. “But the possibilities of oncology are constantly expanding, thanks to new treatment methods, patients with melanoma skin cancer are living longer, which is why doctors are increasingly diagnosing metastases in the brain. In such conditions, one of the top priorities for cancer researchers is to understand the mechanism of melanoma spread to the brain.”
To address this task, Israeli specialists conducted an experiment involving laboratory rodents infected with melanoma. After waiting for the cancer cells to spread into the brain tissue, they began to study the characteristics of their interaction. As a result, the scientists found that melanoma cells enter the brain by deception. The main barrier for them is the blood-brain barrier. This is a kind of filter that prevents dangerous microorganisms and substances circulating in the blood from penetrating the central nervous system.
However, this barrier has gates through which nutrients enter the brain from the arterial circulation. Special cells called astrocytes guard these gates, and their role is to protect the brain and maintain its functions. When they detect any damage to brain tissue, they begin to actively release inflammatory factors, attracting immune cells.
The protein CXCL10 acts as one of these factors, and receptors for it are found on the membranes of immune system cells. By binding to it, they receive a signal to urgently move towards the brain. When they reach their destination, astrocytes open the gates of the blood-brain barrier for them.
A Wolf in Sheep's Clothing
The scientists at Tel Aviv University found that melanoma cells use the same mechanism. They convince astrocytes of the presence of an inflammatory process in brain tissue, causing them to send the corresponding signal to the immune system. The “gate” of the protective barrier opens, but instead of immune cells, a stream of melanoma cells heads through. The latter, as the researchers established, just like the body's protective cells, have receptors for the protein CXCL10 on their surface, allowing them to easily disguise themselves as such, opening a path to the brain.
“The blood-brain barrier is not actually impenetrable,” explains one of the authors of the study. “Its gates open when presented with a special pass. It can be said that by pretending to be immune cells, melanoma uses someone else's pass to deceive its way into the brain.” The scientists also found that skin cancer cells begin to interact with astrocytes even at the early stages of the disease, before it spreads throughout the body.
On the Brink of New Treatment
Understanding the mechanism gives researchers the ability to control it. Thus, having learned the way melanoma cells use to penetrate the brain, they conducted another experiment. Using genetic engineering, they suppressed the production of the receptor for the protein CXCL10 present on the membrane surface of cancer cells, thereby depriving them of the ability to capture signals from astrocytes and respond to them.
As a result, in mice that were implanted with the modified melanoma cells with the inhibited receptor, the number of metastases in the brain was almost halved compared to their counterparts that were transplanted with ordinary, unmodified cancer cells. “The process of metastasizing to the brain has significantly slowed down,” noted the Israeli scientists.
After the study on rodents, the authors repeated it on humans. They studied the same processes in samples of tumour tissue removed from the brains of patients with advanced melanoma. It turned out that in humans, astrocytes produce the same inflammatory factors, and the tumour cells have identical receptors for them. “This means that the discovered link between the protein CXCL10 and its receptor could serve as a potential therapeutic target for preventing the metastasis of melanoma tumours from the skin to the brain,” the scientists assert.